4-Carboxy-α-[3-(hydroxyamino)-3-oxopropyl]-benzenepropanoic acid 1 is a potent hydroxamate-based inhibitor of glutamate carboxypeptidase II. In an attempt to improve its poor oral pharmacokinetics, we synthesized a series of prodrugs by masking its hydrophilic hydroxamate group. Prodrugs were evaluated for oral availability in mice and showed varying degree of plasma exposure to 1. Of these, para-acetoxybenzyl-based, 4-(5-(((4-acetoxybenzyl)oxy)amino)-2-carboxy-5-oxopentyl)benzoic acid, 12, provided 5-fold higher plasma levels of 1 compared to oral administration of 1 itself. Subsequently, para-acetoxybenzyl-based prodrugs with additional ester promoiety(ies) on carboxylate(s) were examined for their ability to deliver 1 to plasma. Isopropyloxycarbonyloxymethyl (POC) ester 30 was the only prodrug that achieved substantial plasma levels of 1. In vitro metabolite identification studies confirmed stability of the ethyl ester of benzoate while the POC group was rapidly hydrolyzed. At oral daily dose-equivalent of 3 mg/kg, 12 exhibited analgesic efficacy comparable to dose of 10 mg/kg of 1 in the rat chronic constrictive injury model of neuropathic pain.

Institute of Biotechnology Academy of Sciences of the Czech Republic vvi 166 10 Prague Czech Republic

Institute of Organic Chemistry and Biochemistry Academy of Sciences of the Czech Republic vvi 166 10 Prague Czech Republic

Zobrazit více v PubMed

Slusher BS, Rojas C, Coyle JT. Glutamate Carboxypeptidase II A2. In: Rawlings ND, Salvesen G, editors. Handbook of Proteolytic Enzymes. Academic Press; New York: 2013. pp. 1620–1627.

Vornov JJ, Hollinger KR, Jackson PF, Wozniak KM, Farah MH, Majer P, Rais R, Slusher BS. Still NAAG′ing after all these years: The continuing pursuit of GCPII inhibitors. Adv Pharmacol. 2016;76:215–255. PubMed

Barinka C, Rojas C, Slusher B, Pomper M. Glutamate carboxypeptidase II in diagnosis treatment of neurologic disorders prostate cancer. Curr Med Chem. 2012;19:856–870. PubMed PMC

Yamamoto T, Nozaki-Taguchi N, Sakashita Y, Inagaki T. Inhibition of spinal N-acetylated-alpha-linked acidic dipeptidase produces an antinociceptive effect in the rat formalin test. Neuroscience. 2001;102:473–479. PubMed

Yamamoto T, Nozaki-Taguchi N, Sakashita Y. Spinal N-acetyl-alpha-linked acidic dipeptidase (NAALADase) inhibition attenuates mechanical allodynia induced by paw carrageenan injection in the rat. Brain Res. 2001;909:138–144. PubMed

Jackson PF, Cole DC, Slusher BS, Stetz SL, Ross LE, Donzanti BA, Trainor DA. Design synthesis and biological activity of a potent inhibitor of the neuropeptidase N-acetylated alpha-linked acidic dipeptidase. J Med Chem. 1996;39:619–622. PubMed

Jackson PF, Tays KL, Maclin KM, Ko YS, Li W, Vitharana D, Tsukamoto T, Stoermer D, Lu XC, Wozniak K, Slusher BS. Design pharmacological activity of phosphinic acid based NAALADase inhibitors. J Med Chem. 2001;44:4170–4175. PubMed

Kozikowski AP, Nan F, Conti P, Zhang J, Ramadan E, Bzdega T, Wroblewska B, Neale JH, Pshenichkin S, Wroblewski JT. Design of remarkably simple yet potent urea-based inhibitors of glutamate carboxypeptidase II (NAALADase) J Med Chem. 2001;44:298–301. PubMed

Majer P, Jackson PF, Delahanty G, Grella BS, Ko YS, Li W, Liu Q, Maclin KM, Polakova J, Shaffer KA, Stoermer D, Vitharana D, Wang EY, Zakrzewski A, Rojas C, Slusher BS, Wozniak KM, Burak E, Limsakun T, Tsukamoto T. Synthesis biological evaluation of thiol-based inhibitors of glutamate carboxypeptidase II: discovery of an orally active GCP II inhibitor. J Med Chem. 2003;46:1989–1996. PubMed

Novakova Z, Wozniak K, Jancarik A, Rais R, Wu Y, Pavlicek J, Ferraris D, Havlinova B, Ptacek J, Vavra J, Hin N, Rojas C, Majer P, Slusher BS, Tsukamoto T, Barinka C. Unprecedented binding mode of hydroxamate-based inhibitors of Glutamate Carboxypeptidase II: Structural characterization biological activity. J Med Chem. 2016;59:4539–4550. PubMed

Vornov JJ, Wozniak KM, Wu Y, Rojas C, Rais R, Slusher BS. Pharmacokinetics pharmacodynamics of the glutamate carboxypeptidase II inhibitor 2-MPPA show prolonged alleviation of neuropathic pain through an indirect mechanism. J Pharmacol Exp Ther. 2013;346:406–413. PubMed PMC

Majer P, Jancarik A, Krecmerova M, Tichy T, Tenora L, Wozniak K, Wu Y, Pommier E, Ferraris D, Rais R, Slusher BS. Discovery of orally available prodrugs of the Glutamate Carboxypeptidase II (GCPII) inhibitor 2-Phosphonomethylpentanedioic Acid (2-PMPA) J Med Chem. 2016;59:2810–2819. PubMed

Majer P, Jackson PF, Delahanty G, Grella BS, Ko Y-S, Li W, Liu Q, Maclin KM, Poláková J, Shaffer KA, Stoermer D, Vitharana D, Wang EY, Zakrzewski A, Rojas C, Slusher BS, Wozniak KM, Burak E, Limsakun T, Tsukamoto T. Synthesis biological evaluation of thiol-based inhibitors of Glutamate Carboxypeptidase II: Discovery of an orally active GCP II inhibitor. J Med Chem. 2003;46:1989–1996. PubMed

Novakova Z, Wozniak K, Jancarik A, Rais R, Wu Y, Pavlicek J, Ferraris D, Havlinova B, Ptacek J, Vavra J, Hin N, Rojas C, Majer P, Slusher BS, Tsukamoto T, Barinka C. Unprecedented binding mode of hydroxamate-based inhibitors of Glutamate Carboxypeptidase II: Structural characterization biological activity. J Med Chem. 2016;59:4539–4550. PubMed

Wiemer AJ, Wiemer DF. Prodrugs of phosphonates phosphates: crossing the membrane barrier. Top Curr Chem. 2014;360:115–160. PubMed PMC

Bennett GJ, Xie YK. A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. Pain. 1988;33:87–107. PubMed

Schlimme S, Hauser AT, Carafa V, Heinke R, Kannan S, Stolfa DA, Cellamare S, Carotti A, Altucci L, Jung M, Sippl W. Carbamate prodrug concept for hydroxamate HDAC inhibitors. ChemMedChem. 2011;6:1193–1198. PubMed

Silhar P, Eubanks LM, Seki H, Pellett S, Javor S, Tepp WH, Johnson EA, Janda KD. Targeting botulinum A cellular toxicity: a prodrug approach. J Med Chem. 2013;56:7870–7879. PubMed PMC

Raji I, Ahluwalia K, Oyelere AK. Design synthesis and evaluation of antiproliferative activity of melanoma-targeted histone deacetylase inhibitors. Bioorg Med Chem Lett. 2017;27:744–749. PubMed PMC

Flipo M, Charton J, Hocine A, Dassonneville S, Deprez B, Deprez-Poulain R. Hydroxamates: relationships between structure plasma stability. J Med Chem. 2009;52:6790–802. PubMed

Attal N, Jazat F, Kayser V, Guilbaud G. Further evidence for ‘pain-related’ behaviours in a model of unilateral peripheral mononeuropathy. Pain. 1990;41:235–251. PubMed

Hargreaves K, Dubner R, Brown F, Flores C, Joris J. A new sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain. 1988;32:77–88. PubMed

Structural, Biochemical, and Computational Characterization of Sulfamides as Bimetallic Peptidase Inhibitors

Combination of In Silico and In Vitro Screening to Identify Novel Glutamate Carboxypeptidase II Inhibitors

Enhanced Oral Bioavailability of 2-(Phosphonomethyl)-pentanedioic Acid (2-PMPA) from its (5-Methyl-2-oxo-1,3-dioxol-4-yl)methyl (ODOL)-Based Prodrugs